Connect with us

Hi, what are you looking for?

Investing

Completion of Divesture of Non-US Assets

Published

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte US” or “the Company”) refers to its announcement released pre-open on 2 October 2024 regarding entry into an Intellectual Property Sales Agreement (the ‘Agreement’) and related documents with Prestige Consumer Healthcare Inc. and associated subsidiaries.

Hydralyte US is pleased to announce that the Agreement has completed and the sale proceeds of approximately US$9.45m (A$13.7m) have been received.

Click here for the full ASX Release

This post appeared first on investingnews.com
In this article:

You May Also Like

Investing

Biren Technology Embarks on IPO Path Amid US Trade Sanctions

Biren Technology, a Chinese artificial intelligence (AI) chip developer seen as a potential rival to industry leader NVIDIA (NASDAQ:NVDA), is making preparations for an...

September 13, 2024

Economy

DEFTF Stock Price and Forecast – Get All The Info

DEFTF Stock Price and Forecast – What Should You Know Have you ever considered investing in the famous DEFTF Stock lately but need to...

September 17, 2024

Economy

Boeing starts furloughing tens of thousands of employees amid machinist strike

Boeing will temporarily furlough thousands of U.S. executives, managers and other staff, citing the ongoing machinist strike as the company races to preserve cash,...

September 19, 2024

Economy

Bitcoin price continues its bullish rally on Wednesday

Bitcoin price continues its bullish rally on Wednesday The price of Bitcoin rose this morning to a new weekly high of $64,795 Bitcoin chart...

September 25, 2024

Disclaimer: Earlyagenda.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2024 Earlyagenda.com